Printer Friendly

CompanyAwarded grant from Maryland Stem Cell Research Fund.

MIAMI, Fla., May 22, 2017 -- Longeveron announced receiving a $750,000 grant from the Maryland Stem Cell Research Fund (MSCRF) to continue its stem cell research.

Longeveron will partner with the University of Maryland and Johns Hopkins University to conduct a clinical trial for hypoplastic left heart syndrome (HLHS), a rare and often fatal condition in infants caused by an underdeveloped heart.

Sunjay Kaushal of the University of Maryland said the HLHS trial "may be a game changing procedure" to improve ventricular performance for, and possibly increase the lifespan of, HLHS babies.

The MSCRF was established by the Governor and the Maryland General Assembly through the Maryland Stem Cell Research Act of 2006 to accelerate research using human stem cells and advance medical treatmen.

Contact: http://www.longeveron com

COPYRIGHT 2017 DataTrends Publications, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Grants & Contracts
Publication:Stem Cell Lab World
Date:May 29, 2017
Words:129
Previous Article:Testing the safety of stem cell therapy for early menopause.
Next Article:Texas about to lower its standards for approving stem cell other therapies.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters